# HtrA2/Omi: potential therapeutic targets for neurodegenerative diseases

**Authors:** Liting Xu, Min Zeng

PMC · DOI: 10.3389/fphar.2026.1705666 · 2026-01-13

## TL;DR

This paper reviews HtrA2/Omi's role in mitochondrial health and its potential as a treatment target for neurodegenerative diseases.

## Contribution

The paper provides new insights into HtrA2/Omi's therapeutic potential by reviewing its structure, regulators, and involvement in neurodegeneration.

## Key findings

- HtrA2/Omi dysfunction is linked to neurodegenerative disease pathogenesis.
- HtrA2's subcellular localization influences cell fate and disease progression.
- Agonists and inhibitors of HtrA2/Omi are identified for potential therapeutic development.

## Abstract

High temperature requirement protein A2 (HtrA2/Omi), a key regulator of mitochondrial quality control, plays a pivotal role in determining cell fate through its subcellular localization, whether mitochondrial or cytosolic. Growing evidence links the absence or dysfunction of HtrA2 to the pathogenesis of neurodegenerative diseases. This review examines the structure and function of HtrA2, highlights its transcriptional regulators, explores its involvement in neurodegeneration, and outlines the currently identified agonists and inhibitors, offering new insights for developing HtrA2/Omi as a potential therapeutic target for neurodegenerative disorders.

## Linked entities

- **Genes:** HTRA2 (HtrA serine peptidase 2) [NCBI Gene 27429], HTRA2 (HtrA serine peptidase 2) [NCBI Gene 27429]

## Full-text entities

- **Genes:** HTRA2 (HtrA serine peptidase 2) [NCBI Gene 27429] {aka MGCA8, OMI, PARK13, PRSS25}
- **Diseases:** neurodegeneration (MESH:D019636)
- **Chemicals:** Omi (-)

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12835204/full.md

---
Source: https://tomesphere.com/paper/PMC12835204